Idenix Pharmaceuticals (IDIX)

[flatlander_60048]

Riba interaction

I read on this board (I believe) that the VX 950 9% discontinuation rate was largely associated with a skin rash SE. Dew (I believe) speculated that this SE might be the result of the VX950 enhancing the action of Riba, since skin rash is a known SE of Riba (in sensitative populations, I guess).

Is this likely to be easily addressed through Riba dosage modulation or are the studies conducted at a minimal dosage that should not be varied? Or is it likely to be a manner of additional trials (time) to determine optimal dosing?

Is it likely that there is a continuum of synergistic vs. antagonistic interaction with the best dosing/interaction performance occurring somewhere in the middle of the spectrum rather than at either of the extremes?

This is probably something that can only be determined with additional testing but I'd be interested in this boards thoughts.

Thanks

FL